Talk to us

Your feedback directly shapes Sporos.

Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments | Sporos

← Back to Regulations

← Rule: Special Conditions: Honeywell Inter…Prev Proposed: Petition for Rulemaking-Amendments …Next →

NoticeRequest for Comment97 days to comment

Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments

The Food and Drug Administration (FDA or the Agency) is announcing the following public meeting titled "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments." The topic to be discussed is the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.

Published

Apr 15, 2026

Comments Close

Jul 23, 2026(97d)

Citation

91 FR 20171

Agencies

2026-07248Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments

Federal Register →PDF Submit Comment

Public Comment Period Open

97 days remaining — closes Jul 23, 2026.

Submit a Comment →

Full text not available in our database.

View on Federal Register →

AI Summary

Get a plain-English explanation of what this regulation does, which agencies are responsible, and how it affects existing rules.

No document text available yet

Agencies (2)

FDA — Food and Drug Administration

HHS — Health and Human Services Department

Docket IDs

Docket No. FDA-2026-N-3273

Document Details

Type: Notice
Action: Notice of public meeting; request for comments.
Document #: 2026-07248
Citation: 91 FR 20171
Publication Date: Apr 15, 2026
Dates: The public meeting will be held on June 23, 2026, from 1:00 p.m. to 2:30 p.m. ET. Either electronic or written comments on this public meeting must be submitted by July 23, 2026. See the SUPPLEMENTARY INFORMATION section for registration date and information.
Federal Register Pages: Vol. 91, pp. 20171–20173
Page Views: 168

Source Links

Federal Register (HTML)Federal Register (PDF)Submit Comment

←

Rule: Special Conditions: Honeywell Inter…

Proposed: Petition for Rulemaking-Amendments …

→